Lawyers handling drug-defect suits say New Jersey courts could see an uptick in volume of pharmaceutical and medical device suits in light of this week’s Supreme Court ruling in a California case that narrowed access to jurisdiction for out-of-state plaintiffs.
The justices’ holding on Monday in Bristol-Myers Squibb v. Superior Court of California, that California courts lacked general jurisdiction over suits by nonresident users of the blood thinner Plavix, will send some plaintiffs scrambling for new venues, lawyers said. And they added that New Jersey’s status as home to numerous major drug companies could prompt more plaintiff lawyers from around the country to file their cases in this state’s courts.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
